Using T-DM1 for treating HER2-positive Breast Cancer
Dr. Julie Gralow discusses newly approved drug T-DM1 and what this means for women living with HER2-positive breast cancer and other breast cancers. This exciting new category of breast cancer drug is an antibody that delivers chemo directly to the cancer cell, leaving the bulk of the body free of exposure to unnecessary chemotherapy. For the 20-25% of breast cancer patients with HER2-positive breast cancer and HER-2 express breast cancer this drug is significantly less toxic on the body. Side effects include a small chance of heart toxicity and a possible decrease in platelets. However, in general the side effects are markedly less than standard chemotherapy treatment with less reports of fatigue, no hair loss and no nausea and vomiting.